首页> 外文期刊>The Journal of Urology >Lymph and blood vessel architecture in benign and malignant prostatic tissue: lack of lymphangiogenesis in prostate carcinoma assessed with novel lymphatic marker lymphatic vessel endothelial hyaluronan receptor (LYVE-1).
【24h】

Lymph and blood vessel architecture in benign and malignant prostatic tissue: lack of lymphangiogenesis in prostate carcinoma assessed with novel lymphatic marker lymphatic vessel endothelial hyaluronan receptor (LYVE-1).

机译:良性和恶性前列腺组织中的淋巴和血管结构:用新型淋巴标记淋巴管内皮透明质酸受体(LYVE-1)评估前列腺癌的淋巴管生成不足。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

PURPOSE: Due to the lack of specific markers the analysis of lymphatic vessel density (LVD) has been almost impossible in the past. We report the novel specific marker for lymphatic endothelium, lymphatic vessel endothelial hyaluronan receptor (LYVE-1), in prostatic, benign prostatic hyperplasia (BPH) and prostate cancer (PCa) tissue. Normal blood vessels were additionally quantified in BPH and PCa. MATERIALS AND METHODS: LYVE-1 lymphatics (LVD) and CD34 blood vessels were assessed in 20 paraffin sections of BPH and 50 of PCa tissue by immunohistochemistry in a standardized experimental setting. The regions of PCa, periphery of the tumor and nontumorous regions of the PCa specimens, and BPH tissue were evaluated. Double staining was done (LYVE-1/CD34). Acquired data were interrelated and compared to the pathological parameters of the specimens. RESULTS: Double staining revealed numerous CD34 blood vessels but only a few LYVE-1 lymphatic vessels in BPH and PCa sections. Mean LVD +/- SD was distinctly lower (0.55 +/- 0.93) in PCa tissue than in tumor periphery (2.45 +/- 1.93) and nontumorous (3.16 +/- 2.23) tissue (p <0.0001). Maximum LVD was observed in BPH (7.17 +/- 3.61), which differed markedly from nontumorous areas of PCa specimens (p <0.001). In contrast to LVD, significantly more blood vessels were found in PCa (116.00 +/- 39.25) than in BPH (60.30 +/- 19.34) tissue (p <0.001). CONCLUSIONS: LYVE-1 is a specific lymphatic endothelial marker in benign and malignant prostate tissues. It is a useful new marker for the investigation of lymphatics. To our knowledge we report the immunohistochemical visualization and quantification of lymphatic vessels in prostatic tissue for the first time. In contrast to the stimulated angiogenesis of blood vessels in PCa, the destruction of lymphatic vessels occurs rather than lymphangiogenesis.
机译:目的:由于缺乏特异性标记,过去几乎不可能进行淋巴管密度(LVD)的分析。我们报告在前列腺,良性前列腺增生(BPH)和前列腺癌(PCa)组织中的淋巴管内皮,淋巴管内皮透明质酸受体(LYVE-1)的新型特异性标记。在BPH和PCa中还对正常血管进行了定量。材料与方法:采用免疫组织化学方法在标准化实验环境中,对BPH的20个石蜡切片和PCa的50个石蜡切片中的LYVE-1淋巴管(LVD)和CD34血管进行了评估。评估PCa的区域,肿瘤周围和PCa标本的非肿瘤区域以及BPH组织。进行了双重染色(LYVE-1 / CD34)。将获得的数据相互关联,并与标本的病理参数进行比较。结果:双染色显示在BPH和PCa切片中有大量CD34血管,但只有少数LYVE-1淋巴管。 PCa组织中的平均LVD +/- SD明显低于肿瘤周围组织(2.45 +/- 1.93)和非肿瘤组织(3.16 +/- 2.23)(p <0.0001)(0.55 +/- 0.93)。在BPH中观察到最大LVD(7.17 +/- 3.61),这与PCa标本的非肿瘤区域明显不同(p <0.001)。与LVD相反,在PCa(116.00 +/- 39.25)中发现的血管明显多于BPH(60.30 +/- 19.34)组织中的血管(p <0.001)。结论:LYVE-1是前列腺组织良性和恶性的特异性淋巴管内皮标志物。它是研究淋巴管学的有用的新标记。据我们所知,我们首次报道了前列腺组织中淋巴管的免疫组织化学显像和定量。与PCa中血管的刺激血管生成相反,发生淋巴管的破坏而不是淋巴管生成。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号